Ultragenyx Pharmaceutical Inc.
RARE
$26.96
$0.160.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -92.00M | -185.00M | -128.56M | -180.41M | -115.00M |
| Total Depreciation and Amortization | 8.00M | 8.00M | 8.79M | 8.61M | 9.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.00M | 31.00M | 19.35M | 25.53M | 20.00M |
| Change in Net Operating Assets | -29.00M | -51.00M | 588.00K | 54.86M | -23.00M |
| Cash from Operations | -97.00M | -197.00M | -99.83M | -91.42M | -109.00M |
| Capital Expenditure | -1.00M | -1.00M | -938.00K | -1.28M | -3.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 45.00M | -48.00M | -71.31M | 118.46M | 74.00M |
| Cash from Investing | 44.00M | -49.00M | -72.25M | 117.18M | 71.00M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3.00M | -- | 2.19M | 2.00K | 84.00M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 392.00M | -- | -- |
| Cash from Financing | 3.00M | -- | 394.19M | 2.00K | 84.00M |
| Foreign Exchange rate Adjustments | 1.00M | -1.00M | -656.00K | 294.00K | 4.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -49.00M | -247.00M | 221.46M | 26.06M | 50.00M |